In preparation for a potential rise in COVID-19 cases during the upcoming fall and winter seasons, Taiwan’s Centers for Disease Control (CDC) has announced an expanded free vaccination campaign starting October 1, 2025, targeting high-risk populations. This policy shift aligns with the global trend of prioritizing vulnerable groups rather than promoting universal immunization.
The announcement follows the June 12 recommendations of Taiwan’s Advisory Committee on Immunization Practices (ACIP), which emphasized a targeted strategy in response to emerging variants and shifting pandemic dynamics.
🧬 What’s New: Focus on the LP.8.1 Variant
The vaccination program will prioritize doses targeting the LP.8.1 variant, a newly emerging subvariant that is gradually replacing the dominant NB.1.8.1 strain in Taiwan. According to the CDC, the LP.8.1-targeted vaccine offers enhanced protection and follows global guidance from the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention, and the European Medicines Agency.
Taiwan plans to procure:
- 2.77 million doses of Moderna’s LP.8.1-targeted mRNA vaccine
- 300,000 doses of Novavax’s JN.1-targeted protein subunit vaccine (for those unable to receive mRNA vaccines)
These will supplement the existing Moderna JN.1 vaccine, which remains available until September 30 for anyone aged 6 months and older.
🛡️ Who is Eligible in Phase 1 (from October 1)?
Ten specific groups will be prioritized for free vaccinations in the first rollout phase:
- Seniors aged 65 and above
- Indigenous people aged 55–64
- Residents and staff in long-term care or nursing homes
- Pregnant women
- Healthcare workers and epidemic prevention personnel
- Childcare staff and nannies
- Parents of infants younger than 6 months
- Children aged 6 months to under 6 years
- High-risk individuals aged 6 months and older, including:
- People with chronic diseases
- Individuals with disabilities
- Mental illness patients
- People with tuberculosis or dementia
- Home-based caregivers
🔁 Phase 2: Adults Aged 50-64
Starting November 1, the program will expand to include adults aged 50-64 who do not have high-risk conditions.
💬 Expert Insights and Public Health Strategy
The CDC’s strategy reflects a cost-effective, impact-driven approach, mirroring similar policies in Europe and the U.S., where blanket vaccination campaigns are being scaled down in favor of targeted protection for the most vulnerable.
Public health experts in Taiwan believe this policy will prevent severe illness and reduce hospital strain, especially as respiratory syncytial virus (RSV) and influenza are also expected to surge during winter.
Dr. Huang Li-min, a virologist from National Taiwan University, notes:
“Targeting vulnerable populations is the most efficient use of vaccines. We must ensure healthcare infrastructure is protected as respiratory viruses converge this winter.”
The government also emphasized that booster dose uptake is key to maintaining community protection, particularly among frontline workers and the elderly.
🧠 FAQs
Why isn’t everyone eligible for a free vaccine this year?
Global health policies are now focusing on protecting high-risk groups as COVID-19 becomes endemic. Universal free vaccination is no longer deemed necessary or cost-effective.
Is the new LP.8.1-targeted vaccine safe?
Yes. The LP.8.1 vaccine is based on updated mRNA platforms used globally. It has passed safety evaluations by major international regulatory agencies.
Can I choose between Moderna and Novavax?
Individuals who cannot receive mRNA vaccines for medical reasons can opt for Novavax’s protein-based option.
Will pharmacies offer these vaccines?
Vaccines will be available through local health departments, designated hospitals, and some pharmacies. The CDC will publish an official list.
Will proof of eligibility be required?
Yes. Documentation such as National Health Insurance cards, caregiver identification, or birth records for infants will be needed for verification.
